How insights about living with asthma were used to segment patients and raise awareness across Asia
Our client wanted to explore attitudes to living with asthma across Asia amongst both patients and physicians. They also wanted to segment patients in order to understand the differences in attitudes and determine what support was needed across the region.
As well as answering the client’s objectives, this study needed to be fit for scientific publication and for use at international asthma congresses.
Christelle Malingrey appointed new Fieldwork Manager
Research Partnership is delighted to welcome Christelle Malingrey to the company’s London headquarters in the role of Fieldwork Manager.
Christelle joins with more than 10 years experience in market research. She brings with her a wealth of fielding expertise in the EU and US markets across various areas, including team management, panel management and project feasibility.
Biosimilars 2015: Do our research findings suggest a step change in the market?
Q1 2015 has seen big changes for the biosimilar market, and with regulatory pathways now developed almost across the world we can see that biosimilars are becoming more widely accepted.
Laurent Chanroux, Research Director of Therapy Watch, looks at what has happened in 2015 to date and investigates how changes in the RA landscape are impacting rheumatologists’ likelihood to prescribe a biosimilar, using data taken from our Therapy Watch RA patient research study.
Digital Services Group established
Research Partnership has formed a Digital Services Group.
Led by Director John Branston, the group will build on existing capabilities and explore the latest digital research approaches in order to develop and apply these advanced techniques within pharmaceutical market research.
Turkey: Identifying the Growth Drivers
Published in eyeforpharma 3 April by Paul Reed
Last year, I concluded my series of articles outlining the challenges and opportunities for pharma in the “MINT” countries, by stating that aggressive pricing controls and dominance of generic drugs means that in the immediate future the greatest opportunity for branded, innovative drugs lies in the private sector.